Japan said on Friday it would consider sharing the COVID-19 vaccine with other countries, while a political party committee called for part of AstraZeneca Plc (A.N) vaccine to be supplied to Taiwan.
Taiwan is battling the rise of domestic infections. and only 1% of the population has been vaccinated. While Japan has received more than 400 million doses, doubling the demand for the adult population. Read more
“We think it is important to ensure access to safe and effective vaccines in all countries and regions. to achieve universal health protection,” said Katsunobu Kato, Chief Cabinet Secretary of Japan. said in a press release
“We will take a quick look and consider concrete policies on how we provide vaccines to other countries and regions that exceed the doses required at home.”
Masahisa Sato, head of Japan’s ruling party committee on Taiwan relations, said early on Friday that the government should vaccinate Taiwan as soon as possible, adding: “When Japan needs Taiwan, Taiwan sent us 2 million masks.
Kato declined to comment on whether Tokyo had received sourcing requests from some countries.
Taiwan’s foreign ministry said the government is working hard to obtain the vaccine, either through the manufacturer or the COVAX global sharing program.
Taipei also seeks “Country like-minded to help get vaccinated. And the effort has not stopped,” the report added.
Japan approved AstraZeneca’s vaccine last week and has signed a contract to buy 120 million doses, but has no immediate plans to use it in the country. Amid ongoing international concerns about blood clots Read more
AstraZeneca’s local partner Daiichi Sankyo Co (DAIC.N) began bottling the vaccine in March. And it currently has approximately 30 million doses in stock, which will expire in September if they are not used.
Volumes are set to increase as AstraZeneca added Nipro Corp (NIPRO.N) this week as its third local partner to carry out vaccine containment and repackage. Read more
Japan began its vaccination drive in mid-February. slower than most major economies and using imported doses from shots developed by Pfizer Inc (Pfizer Inc.) and BioNTech SE (22UAy.DE).
A vaccine developed by Moderna (Mod.N) was also introduced this week with the opening of a number of vaccination centers.
Japan received 10.6 million doses of the vaccine as of Wednesday. About one-sixth of all vaccines imported to date. based on government data and schedule by September The projected supply will reach 414 million doses, doubling what the country needs for its adult population.
Prime Minister Yoshihide Suka will host a summit on June 2 on the provision of vaccines to countries in need through the WHO’s COVAX program. So far, Japan has pledged to fund the program. but no vaccine
Japan will likely keep AstraZeneca’s adenovirus shots for people allergic to mRNA vaccines from Pfizer or Moderna, and distribute the rest, said Haruka Sakamoto, a physician and researcher at Keio University in Tokyo.
“Japan may announce that they will donate the AZ vaccine they already have contracts for and supply COVAX with the AZ vaccine they will produce in Japan,” she said.
An AstraZeneca spokeswoman said it was up to the Japanese government how to use the dosage.
Our Standard: The Thomson Reuters Trust Principle.